This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $509,038.00 to Ceiba Bio Inc. to develop a blood-based "exercise mimetic" treatment for Alzheimer's disease and related dementias. The key objectives are to: 1) identify 3 lead recombinant human GPLD1 molecules, 2) establish optimal exposure through in vivo PK profiling in aged mice, and 3) test 2 lead GPLD1 molecules for disease modification in an Alzheimer's mouse model. Successful completion of these aims is a critical first step towards commercializing potential therapeutic blood-based exercise mimetics to treat Alzheimer's and related dementias. The funding is provided for the period of September 1, 2024 to August 31, 2025.
Generated 3/4/25, 5:24 AM